Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ)
ValueMarkers Composite Index
59% below intrinsic value ($5)
Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) — VMCI valuation read
Across 120 indicators, Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) lands at VMCI 50/100. The Healthcare sector median is 50, so the 0-point above-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.
No material Form 4 disclosures landed on 300122.SZ in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.
**Investor frame.** On Value, 300122.SZ trades at 27.0x earnings, 50% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%). On Risk, net debt to EBITDA of 3.0x is the rate-sensitivity line to watch for 300122.SZ on the trailing balance sheet.
300122.SZ rose 1.5% over the trailing 7 days, with a +4.8% read on a 30-day basis.
Chongqing Zhifei Biological Products Co., Ltd. engages in the research, development, manufacture, and marketing of vaccines and biological products in China. The company was founded in 2009 and is based in Chongqing, China.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.